About TriSalus Life Sciences
TriSalus Life Sciences is a company based in Westminster (United States) founded in 2009.. TriSalus Life Sciences has raised $83.37 million across 12 funding rounds from investors including MCG Capital, Nantahala Capital Management and Broadfin Capital. The company has 110 employees as of December 31, 2024. TriSalus Life Sciences offers products and services including Drug Delivery Technology, nelitolimod, and TriNav Infusion System. TriSalus Life Sciences operates in a competitive market with competitors including Insulet, Lyra Therapeutics, Credence MedSystems, Foresee Pharmaceuticals and Cellectar Biosciences, among others.
- Headquarter Westminster, United States
- Employees 110 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Trisalus Life Sciences, Inc.
-
Annual Revenue
$29.43 M58.99as on Dec 31, 2024
-
Net Profit
$-30.05 M49.39as on Dec 31, 2024
-
EBITDA
$-35.16 M33.15as on Dec 31, 2024
-
Total Equity Funding
$83.37 M (USD)
in 12 rounds
-
Latest Funding Round
$22 M (USD), Post-IPO
Apr 30, 2025
-
Investors
MCG Capital
& 8 more
-
Employee Count
110
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of TriSalus Life Sciences
TriSalus Life Sciences is a publicly listed company on the NASDAQ with ticker symbol TLSI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of TriSalus Life Sciences
TriSalus Life Sciences offers a comprehensive portfolio of products and services, including Drug Delivery Technology, nelitolimod, and TriNav Infusion System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for enhancing drug delivery to tumors.
Candidate therapy for liver and pancreatic tumor treatment.
System for pressure-enabled drug administration in tumors.
Unlock access to complete
Unlock access to complete
Funding Insights of TriSalus Life Sciences
TriSalus Life Sciences has successfully raised a total of $83.37M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $22 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Post-IPO — $22.0M
-
First Round
First Round
(26 Apr 2011)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2025 | Amount | Post-IPO - TriSalus Life Sciences | Valuation | Nantahala Capital Management | |
| Dec, 2024 | Amount | Post-IPO - TriSalus Life Sciences | Valuation |
investors |
|
| Oct, 2022 | Amount | Post-IPO - TriSalus Life Sciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TriSalus Life Sciences
TriSalus Life Sciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include MCG Capital, Nantahala Capital Management and Broadfin Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment opportunities in healthcare are managed by Broadfin Capital.
|
Founded Year | Domain | Location | |
|
A venture capital firm focused on early-stage biotech investments.
|
Founded Year | Domain | Location | |
|
Healthcare investments are made by Tullis Health Investors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TriSalus Life Sciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TriSalus Life Sciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Trisalus Life Sciences Comparisons
Competitors of TriSalus Life Sciences
TriSalus Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Lyra Therapeutics, Credence MedSystems, Foresee Pharmaceuticals and Cellectar Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for ENT diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of smart devices for drug delivery
|
|
| domain | founded_year | HQ Location |
Injectables and NCEs for cancer and chronic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Phospholipid drug conjugates for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Trisalus Life Sciences
Frequently Asked Questions about TriSalus Life Sciences
When was TriSalus Life Sciences founded?
TriSalus Life Sciences was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Where is TriSalus Life Sciences located?
TriSalus Life Sciences is headquartered in Westminster, United States.
Is TriSalus Life Sciences a funded company?
TriSalus Life Sciences is a funded company, having raised a total of $83.37M across 12 funding rounds to date. The company's 1st funding round was a Post-IPO of $15.32M, raised on Apr 26, 2011.
How many employees does TriSalus Life Sciences have?
As of Dec 31, 2024, the latest employee count at TriSalus Life Sciences is 110.
What is the annual revenue of TriSalus Life Sciences?
Annual revenue of TriSalus Life Sciences is $29.43M as on Dec 31, 2024.
What does TriSalus Life Sciences do?
TriSalus Life Sciences is involved in developing drug delivery devices to treat cancers. They have developed a technology platform, Pressure-Enabled Drug Delivery (PEDD), which is designed to improve the distribution and penetration of therapy in solid tumors.
Who are the top competitors of TriSalus Life Sciences?
TriSalus Life Sciences's top competitors include Insulet, Lyra Therapeutics and Mercator MedSystems.
What products or services does TriSalus Life Sciences offer?
TriSalus Life Sciences offers Drug Delivery Technology, nelitolimod, and TriNav Infusion System.
Is TriSalus Life Sciences publicly traded?
Yes, TriSalus Life Sciences is publicly traded on NASDAQ under the ticker symbol TLSI.
Who are TriSalus Life Sciences's investors?
TriSalus Life Sciences has 9 investors. Key investors include MCG Capital, Nantahala Capital Management, Broadfin Capital, ORI Capital, and Tullis Health Investors.
What is TriSalus Life Sciences's ticker symbol?
The ticker symbol of TriSalus Life Sciences is TLSI on NASDAQ.